FDA issues letter regarding lebrikizumab review for atopic dermatitis.

In the press release, the company said it would work withthe third-party manufacturer and the FDA to address thefeedback "in order to make lebrikizumab available topatients". Latest News The Food and Drug Administration has issued a completeresponse letter regarding lebrikizumab, aninvestigational biologic for the treatment of adult andadolescent patients with moderate to severe atopicdermatitis, describing concerns about findings madeduring an inspection of a third-party contractmanufacturer that included the "monoclonal antibody drugsubstance" for lebrikizumab, Eli Lilly announced in anOct. [Extracted from the article]